by Kevin Dooley, MD | Mar 30, 2021 | News and Information
Negative Results The biotech company Orphazyme announced negative results yesterday for the clinical trial of arimoclomol in the treatment of inclusion body myositis (IBM). The drug failed to meet the primary and secondary endpoints which were used to measure success.... 
by Kevin Dooley, MD | Jan 29, 2020 | News and Information
A recently published study finds that the Inclusion Body Myositis Functional Rating Scale (IBMFRS) does not correlate as well as expected with measures of grip strength and finger flexor strength. This suggests that the IBMFRS could be improved to more accurately... 
by Kevin Dooley, MD | Nov 5, 2018 | News and Information
How do you know if a muscle disease like inclusion body myositis (IBM) is getting worse? How do you compare one patient to another? How do you decide if a new drug is working to slow the gradually worsening muscle weakness that is typical of this disease? How do you... 